We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aquestive Therapeutics (AQST) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Aquestive Therapeutics (AQST - Free Report) closed the most recent trading day at $1.64, moving +1.86% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.71%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 4.62%.
Prior to today's trading, shares of the specialty pharmaceutical company had lost 25.46% over the past month. This has lagged the Medical sector's loss of 1.53% and the S&P 500's gain of 2.65% in that time.
Aquestive Therapeutics will be looking to display strength as it nears its next earnings release. In that report, analysts expect Aquestive Therapeutics to post earnings of -$0.11 per share. This would mark year-over-year growth of 69.44%. Our most recent consensus estimate is calling for quarterly revenue of $10.76 million, down 18.91% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.29 per share and revenue of $42.72 million, which would represent changes of +74.11% and -10.4%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Aquestive Therapeutics. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Aquestive Therapeutics is currently a Zacks Rank #1 (Strong Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aquestive Therapeutics (AQST) Outpaces Stock Market Gains: What You Should Know
Aquestive Therapeutics (AQST - Free Report) closed the most recent trading day at $1.64, moving +1.86% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.71%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 4.62%.
Prior to today's trading, shares of the specialty pharmaceutical company had lost 25.46% over the past month. This has lagged the Medical sector's loss of 1.53% and the S&P 500's gain of 2.65% in that time.
Aquestive Therapeutics will be looking to display strength as it nears its next earnings release. In that report, analysts expect Aquestive Therapeutics to post earnings of -$0.11 per share. This would mark year-over-year growth of 69.44%. Our most recent consensus estimate is calling for quarterly revenue of $10.76 million, down 18.91% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.29 per share and revenue of $42.72 million, which would represent changes of +74.11% and -10.4%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Aquestive Therapeutics. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Aquestive Therapeutics is currently a Zacks Rank #1 (Strong Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.